Parkman Healthcare Partners LLC Invests $20.45 Million in IQVIA Holdings Inc. $IQV

Parkman Healthcare Partners LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 105,811 shares of the medical research company’s stock, valued at approximately $20,445,000. IQVIA comprises approximately 2.1% of Parkman Healthcare Partners LLC’s holdings, making the stock its 15th biggest position. Parkman Healthcare Partners LLC owned 0.06% of IQVIA at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IQV. Brighton Jones LLC boosted its stake in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC increased its position in IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC bought a new position in IQVIA in the 2nd quarter valued at approximately $514,000. First Trust Advisors LP boosted its position in IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after buying an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its position in IQVIA by 5.4% in the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after buying an additional 1,155 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on IQV shares. BMO Capital Markets upped their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Stifel Nicolaus raised their price objective on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. William Blair raised IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. HSBC reiterated a “buy” rating and issued a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Finally, TD Cowen lifted their price target on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Price Performance

Shares of NYSE:IQV opened at $260.30 on Tuesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $261.88. The firm has a market cap of $42.85 billion, a PE ratio of 32.30, a price-to-earnings-growth ratio of 2.21 and a beta of 1.18. The firm’s fifty day moving average is $214.97 and its 200-day moving average is $187.62.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its board has initiated a stock repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In related news, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares in the company, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 12,913 shares of company stock valued at $3,098,793 over the last three months. 1.70% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.